Simple calculations of direct impact for the initial assessment of the value of primary HIV prevention interventions

preprint OA: closed CC-BY-NC-ND-4.0
📄 Open PDF Full text JSON View at publisher

Abstract

Introduction Over the course of the HIV pandemic prevention and treatment interventions have reduced HIV incidence but there is still scope for new prevention tools to further control HIV. Studies of the transmission dynamics and cost effectiveness of HIV prevention tools are often done using detailed complex models but there is a role for simpler earlier analyses. Methods Equations are defined to calculate the cost effectiveness, budget impact, and epidemiological impact of HIV prevention interventions including equations allowing for multiple interventions and heterogeneity in risk across populations. An efficiency ratio of primary HIV prevention and IV treatment as prevention is defined. Results As HIV incidence declines the number needed to treat to prevent one HIV infection increases. The cost effectiveness of HIV is driven by incidence, along with efficacy, duration, and costs of the intervention. The budget impact is driven by cost, size of the population and coverage achieved, and impact is determined by the effective coverage of interventions. Heterogeneity in risk could in theory allow for targeting primary HIV prevention but current screening tools do not appear to sufficiently differentiate risk in populations where they have been applied. Discussion Simple calculations provide a tool to readily assess the cost-effectiveness, impact, and budget impact of HIV prevention interventions and can include heterogeneities in risk of HIV acquisition. These calculations provide rough initial estimates that can be compared with more sophisticated transmission dynamic and health economic models. Conclusion HIV incidence is declining making primary prevention tools less cost effective. If we require prevention to be more cost effective either we need to target primary prevention tools or they need to be less expensive. Simple equations allow for an exploration of the cost effectiveness of HIV interventions but the sensitivity of results to assumptions needs to be tested by comparison with transmission dynamic models.
Full text 3,444 characters · extracted from oa-doi-fallback · 5 sections · click to expand

Abstract

Introduction Over the course of the HIV pandemic prevention and treatment interventions have reduced HIV incidence but there is still scope for new prevention tools to further control HIV. Studies of the transmission dynamics and cost effectiveness of HIV prevention tools are often done using detailed complex models but there is a role for simpler earlier analyses.

Methods

Equations are defined to calculate the cost effectiveness, budget impact, and epidemiological impact of HIV prevention interventions including equations allowing for multiple interventions and heterogeneity in risk across populations. An efficiency ratio of primary HIV prevention and IV treatment as prevention is defined.

Results

As HIV incidence declines the number needed to treat to prevent one HIV infection increases. The cost effectiveness of HIV is driven by incidence, along with efficacy, duration, and costs of the intervention. The budget impact is driven by cost, size of the population and coverage achieved, and impact is determined by the effective coverage of interventions. Heterogeneity in risk could in theory allow for targeting primary HIV prevention but current screening tools do not appear to sufficiently differentiate risk in populations where they have been applied.

Discussion

Simple calculations provide a tool to readily assess the cost-effectiveness, impact, and budget impact of HIV prevention interventions and can include heterogeneities in risk of HIV acquisition. These calculations provide rough initial estimates that can be compared with more sophisticated transmission dynamic and health economic models.

Conclusion

HIV incidence is declining making primary prevention tools less cost effective. If we require prevention to be more cost effective either we need to target primary prevention tools or they need to be less expensive. Simple equations allow for an exploration of the cost effectiveness of HIV interventions but the sensitivity of results to assumptions needs to be tested by comparison with transmission dynamic models. Competing Interest Statement The authors have declared no competing interest. Funding Statement This study did not receive any funding. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present work are contained in the manuscript

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00
unpaywall
last seen: 2026-05-27T02:00:06.600101+00:00
License: CC-BY-NC-ND-4.0